Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient

Clinical Drug Investigation

Volumn 29, Issue 7, 2009, Pages 481-486

  Billaud, E M ^a,b   Antoine, C ^c   Berge, M ^a   Abboud, I ^c   Lefeuvre, S ^a,b   Benammar, M ^a   Glotz, D ^c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIFUNGAL AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; ITRACONAZOLE; POSACONAZOLE; THYMOCYTE ANTIBODY; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; HEALTH CARE COST; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS INFECTION; WEGENER GRANULOMATOSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PYRIMIDINES; SIROLIMUS; TRIAZOLES;

EID: 67650318484     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/00044011-200929070-00006     Document Type: Article

References (26)

1. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 Jan; 18 (1): 44 -69
2. Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43 (1): S28-39
3. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society. Clin Infect Dis 2008 Feb; 46 (3): 327-60
4. Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006 Apr; 7 (6): 639-51
5. Keating GM. Posaconazole. Drugs 2005; 65 (11): 1553-67
6. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005 Jan; 22 (1): 11-23
7. Marty FM, Rubin RH. The prevention of infection posttransplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int 2006 Jan; 19 (1): 2-11
8. Romero AJ, Pogamp PL, Nilsson LG, et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002 Apr; 71 (4): 226-34
9. Tintillier M, Kirch L, Goffin E, et al. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005 Mar; 20 (3): 664-5
10. Mathis AS, Shah NK, Fiedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004 Nov; 36 (9): 2708-9
11. Sansone-Parsons A, Krishna G, Martinho M. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007 Jun; 27 (6): 825-34
12. Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006; 66 (4): 547-70
13. Certican® (everolimus) 0.5mg oral tablets [summary of product characteristics]. Rueil-Malmaison, France: Novartis France, 2004
14. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008 Jan; 61 (1): 17-25
15. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oraldose escalation regimens. Antimicrob Agents Chemother 2002 Aug; 46 (8): 2546-53
16. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005 Mar; 35 (5): 509-13
17. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006 May; 12 (5): 552-9
18. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 Apr; 50 (4): 1570-2
19. Imhof A, Schaer DJ, Schwarz U, et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006 Nov 11; 136: 739-42
20. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008 Jan 15; 46 (2): 201-11
21. Boussaud V, Daudet N, Lillo A, et al. Painful sensory neuropathy in lung transplanted patients under voriconazole. J Heart Lung Transplant 2008; 27 (2): 229-32
22. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30 (2): 167-72
23. Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006 Dec; 27 (9): 421-6
24. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41 (11): 813-51
25. Noxafil® (posaconazole) 40mg/mL oral suspension [summary of product characteristics]. Brussels, Belgium: Schering-Plough Europe, 2006
26. Vfend® (voriconazole) 200 mg oral tablets [summary of product characteristics]. Paris, France: Pfizer Europe, 2002